Exonhit (now Diaxonhit) acquires leading independent distributor of in-vitro diagnostics in French market, InGen BioSciences
Client(s) Exonhit S.A. (now Diaxonhit)
Jones Day advised Exonhit SA (now Diaxonhit), a French leader in the field of in-vitro diagnostic listed on the Alternext market of NYSE Euronext Paris, in connection with the €18 million (US$22.9 million) acquisition of InGen BioSciences, the leading independent distributor of in-vitro diagnostics in the French market.